Background
==========

As the third most common malignancy, colorectal carcinoma is the fourth leading cause of cancer-related death worldwide \[[@b1-medscimonit-22-3915]\]. In China, colorectal carcinoma has been ranked as the fifth most common human malignant disease, accounting for 6.51% of mortality in urban areas and 4.64% in rural areas \[[@b2-medscimonit-22-3915]\]. The etiology of colorectal cancers is known to be heterogeneous and various mechanisms have been associated with the increased risk for development and progression of colorectal carcinoma, as well as the aggressive behaviors of the tumors \[[@b3-medscimonit-22-3915]--[@b5-medscimonit-22-3915]\]. Tumors at the invasive front appear morphologically more poorly differentiated and show different molecular characteristics \[[@b6-medscimonit-22-3915]\]. Previous studies of colorectal carcinoma have suggested the potential role of β-tubulin expression in rectal cancer development \[[@b7-medscimonit-22-3915],[@b8-medscimonit-22-3915]\]. A study by Portyanko et al. found expression of class III β-tubulin (βIII-tubulin, also known as TUBB3) at the invasive margin of colorectal cancer \[[@b9-medscimonit-22-3915]\]. However, the authors mainly focused on the immunoreactivity of βIII-tubulin in colorectal cancer patients, and the clinical implication of their findings has not been well investigated. Recently, Mariani et al. investigated the role of βIII-tubulin as a predictive biomarker \[[@b10-medscimonit-22-3915]\]. The distribution of tubulin has also been reported in human leukemia cell line HL-60 \[[@b11-medscimonit-22-3915]\]. However, the potential effect of βIII-tubulin expression at the invasive margin of colorectal cancer was not taken into consideration. Therefore, the present investigated the clinical implication of βIII-tubulin expression at the invasive margin of colorectal cancer.

Material and Methods
====================

Patients and tissue samples
---------------------------

This was a retrospective cohort study. A total of 111 patients with colorectal carcinoma who underwent radical colorectal resection were recruited at Beijing Tongren Hospital from February 2012 to February 2015. We excluded patients with tumor history, familial polyposis colon cancer, Crohn's disease, malignant transformation of ulcerative colitis, simultaneous multiple primary tumors, or incomplete clinical data. The formalin-fixed and paraffin-embedded tissue samples containing the invasive part of the tumors were obtained and stained with hematoxylin and eosin (HE).

Immunohistochemical assay
-------------------------

Immunohistochemical staining of βIII-tubulin was performed with the method of immunohistochemistry envision-two steps using MaxVision™2 (Fuzhou Maixin Biotech. Co., Ltd., Fujian, China) according to the manufacturer's instructions. Briefly, the tissue specimen was cut into 4-μm-thick sections, and deparaffinized in xylene and later rehydrated in graded alcohol. Antigen was retrieved using citrate buffer (pH 6.0) in a microwave oven. After washing 3 times with Tris-buffered saline (TBS), the sections were processed with 3% hydrogen peroxide for 5--10 min to block endogenous peroxidase activity. Sections were then incubated with mouse anti-human antibody against βIII-tubulin (Clone TuJ-1, MAB-0636, Fuzhou Maixin Biotechnology Development Co., Ltd., Fuzhou, China) or cytokeratin (AE1/AE3, KIT-0009, Fuzhou Maixin Biotech Co., Ltd., Fujian, China) overnight at 4°C, followed by horseradish peroxidase-linked sheep anti-mouse secondary antibody (KIT-5930-1, Fuzhou Maixin Biotech Co., Ltd., Fujian, China) for 60 min. The reactions were visualized by 3, 3-diaminobenzidine (DAB). The slides were then counterstained with hematoxylin. The same procedure with the primary antibody omitted was used as a negative control. Sections of peripheral nerve tissue were used as a positive control.

Staining evaluation
-------------------

Expression of βIII-tubulin was analyzed under an Olympus BX51 microscope (Olympus, Tokyo, Japan) by 2 senior professional physicians who were blinded to the clinical data of patients. The proportion of positive tumor cells was scored from 5 randomly selected slides and the results were expressed as the average of data of the 2 physicians. The cytoplasmatic staining intensity was graded as: negative (−, no staining), weak positive (+, pale yellow), moderate positive (++, claybank), and strong positive (+++, sepia).

Study group and follow-up
-------------------------

According to the distribution of βIII-tubulin in the tumor tissue, patients were assigned to either the invasive front group or the non-invasive front group. The invasive front group consisted of cases with βIII-tubulin-positive tumor cells found only in the invasive front tumor area, while the non-invasive front group consisted of the remaining cases. The invasive front was defined as the advancing edge of the tumor. We recorded clinical data on age, sex, tumor size, differentiation status, TNM stage, and lymphatic metastasis. Enrolled patients were followed up from the time of disease diagnosis to the time of death of patients or study deadline (May 2015). This study was approved by the Ethics Committee of Beijing Tongren Hospital of the Capital Medical University and informed consent was obtained from all patients.

Statistical analysis
--------------------

Qualitative data are expressed as proportion and analyzed by χ^2^ or Fisher's exact test. Normally distributed quantitative data are expressed as mean ±SD and analyzed by ANOVA. Data with abnormal distribution are expressed as interquartile range and were analyzed by Kruskal-Wallis test. Correlations analysis was performed by Spearman's or Pearson's test. P \<0.05 was considered statistically significant.

Results
=======

Clinical data
-------------

A total of 111 patients who underwent radical colorectal resection were included in this study. There were 55 males and 56 females. Mean age of the patients was 66.41±12.64 years (median: 68.00). Clinical data are summarized in [Table 1](#t1-medscimonit-22-3915){ref-type="table"}. βIII-tubulin was positively stained in 0.31±0.27% of the tumor cells. The staining intensity was negative in 6 cases (5.41%), weakly positive in 10 cases (9.01%), moderately positive in 65 cases (58.56%), and strongly positive in 30 cases (27.03%). The invasive front group had 72 patients with βIII-tubulin expressed only in the invasive front of tumor tissue, and the non-invasive front group had the remaining 39 patients. HE staining results of colorectal cancer in the non-invasive front group and the invasive front group are shown in [Figure 1A and 1B](#f1-medscimonit-22-3915){ref-type="fig"}. Immunohistochemical analysis showed positive staining of cytokeratin (AE1/AE3) in the non-invasive front group ([Figure 1C](#f1-medscimonit-22-3915){ref-type="fig"}) and the invasive front group ([Figure 1D](#f1-medscimonit-22-3915){ref-type="fig"}). Immunohistochemical analysis of βIII-tubulin showed heterogeneous labeling in both the non-invasive front group and invasive front group, with weakly, moderately, and strongly stained areas observed ([Figure 1E--1J](#f1-medscimonit-22-3915){ref-type="fig"}).

Positive staining and staining intensity of βIII-tubulin in colorectal carcinoma patients
-----------------------------------------------------------------------------------------

The rate of positive staining of βIII-tubulin in colorectal carcinoma patients was significantly correlated with staining intensity and tissue distribution of βIII-tubulin expression (p=0.018 and p=0.001, respectively, [Table 2](#t2-medscimonit-22-3915){ref-type="table"}). The positive staining rate of βIII-tubulin was significantly higher in tumor tissues with higher staining intensity (p\<0.05). The rate of βIII-tubulin positive staining in the non-invasive front group was also significantly higher when compared with the invasive front group. The other data (age, sex, lymphatic metastasis, TNM stage, local recurrence, distant metastasis, and mortality) were not found to be significantly associated with positive staining of βIII-tubulin. There was no significant difference in the clinical data among the groups with different βIII-tubulin staining intensity ([Table 3](#t3-medscimonit-22-3915){ref-type="table"})

Tissue distribution of βIII-tubulin in colorectal carcinoma patients
--------------------------------------------------------------------

The patients were further divided into invasive front and non-invasive front groups according to the tissue distribution of βIII-tubulin in colorectal carcinoma. The rate of positive staining and staining intensity of βIII-tubulin were significantly different between the invasive and non-invasive front groups (p=0.001 and p=0.006, respectively, [Table 4](#t4-medscimonit-22-3915){ref-type="table"}, [Figure 2A, 2B](#f2-medscimonit-22-3915){ref-type="fig"}), and there was a significant difference in tumor differentiation between the 2 groups (p=0.032, [Figure 2C](#f2-medscimonit-22-3915){ref-type="fig"}). However, the differences in other data between the invasive and non-invasive front groups did not reach statistical significance.

Clinical analysis of βIII-tubulin staining intensity in invasive and non-invasive front groups
----------------------------------------------------------------------------------------------

Staining intensity of βIII-tubulin in patients in the invasive and non-invasive front groups was further analyzed. As shown in [Table 5](#t5-medscimonit-22-3915){ref-type="table"}, in the non-invasive front group, staining intensity of βIII-tubulin was significantly associated with the rates of βIII-tubulin-positive staining and lymphatic metastasis of tumors (p\<0.001 and p=0.048, respectively, [Figure 2D](#f2-medscimonit-22-3915){ref-type="fig"}), but there were no significant differences in any of the clinical data with respect to the βIII-tubulin staining intensity in patients in the invasive front group.

Discussion
==========

βIII-tubulin is one of 9 β-isoforms that participate in formation of microtubules; it is known to play a critical role in cell growth, division, motility, signaling development, and cell shape maintenance \[[@b12-medscimonit-22-3915]\]. Overexpression of βIII-tubulin was originally identified to be a prominent factor contributing to resistance to taxane drugs \[[@b13-medscimonit-22-3915]--[@b18-medscimonit-22-3915]\]. Down-regulation of βIII-tubulin expression has been reported to contribute to favorable clinical outcome following anti-tubulin therapy \[[@b14-medscimonit-22-3915]\]. Recently, however, increasing studies have shown that βIII-tubulin is involved more in tumor development and progression than as a predictor of response to chemotherapy in various types of tumors \[[@b18-medscimonit-22-3915]--[@b23-medscimonit-22-3915]\]. βIII-tubulin has been reported to be expressed in a variety of tumors, especially in those with aggressive behavior that are likely to metastasize \[[@b24-medscimonit-22-3915]--[@b26-medscimonit-22-3915]\]. In the present study, the tissue distribution of class III β-tubulin expression at the invasive margin or diffuse distribution was investigated in colorectal cancer. Our study showed that βIII-tubulin was expressed at the invasive margin in 64.78% of our colorectal cancer cases. The expression of βIII-tubulin may be involved with tumor differentiation and lymphatic metastasis, suggesting a potential role of βIII-tubulin in tumor differentiation and metastasis.

In colorectal cancer, aberrant βIII-tubulin expression has been suggested to be involved with tumor development and poor survival of the patients \[[@b8-medscimonit-22-3915],[@b10-medscimonit-22-3915]\]. However, a previous study of βIII-tubulin expression in colorectal cancer indicated that expression of βIII-tubulin was relatively uncommon in colorectal carcinomas \[[@b7-medscimonit-22-3915]\]. A study by Portyanko et al. showed the preferential localization of βIII-tubulin at the invasive margin in colorectal cancer, suggesting a potential role of βIII-tubulin in modulation of the invading activity of cancer cells \[[@b9-medscimonit-22-3915]\]. However, those studies had relatively small sample sizes and the clinical implications of βIII-tubulin at the invasive margin in colorectal cancer had not yet been defined. Therefore, in the present study, 111 patients with surgically resected colorectal cancer were recruited, and the expression of βIII-tubulin at the invasive margin was investigated. The findings of our study showed that βIII-tubulin was expressed at the invasive margin in 72 of 111 cases of colorectal cancer, accounting for 64.87% of all cases. These data dramatically differed from the results reported by Portyanko et al., which showed βIII-tubulin expression at the invasive margin in 28 of 29 cases of colorectal cancer \[[@b9-medscimonit-22-3915]\]. These conflicting results can be partially explained by differences in race and number of patients recruited, as well as the lack of consistency in study criteria. However, despite these differences, our study showed a significant difference in tumor differentiation between the invasive front and non-invasive front groups, with many more poorly and moderately differentiated tumors identified in the invasive front group. This finding was partially corroborated with the results of a previous study reporting more βIII-tubulin immunoreactivity in poorly differentiated colorectal carcinomas \[[@b7-medscimonit-22-3915]\]. Sex has been recently suggested to play a role in the ability of βIII-tubulin to predict poor outcome in colorectal cancer \[[@b10-medscimonit-22-3915]\]. In our study, however, no such sex-related difference was observed. The upregulated expression of βIII-tubulin has been reported in several types of cancers and was associated with aggressive behavior. A previous papillary thyroid carcinoma study showed strong staining of βIII-tubulin in widely infiltrating PTCs, particularly at the invasive margin, or in moderately differentiated PTCs, and most cases with lymphatic metastasis showed strong βIII-tubulin immunoreactivity \[[@b27-medscimonit-22-3915]\]. In an esophageal squamous cell carcinoma study, Yu et al. found that βIII-tubulin expression was associated with the lymphatic metastasis of tumors \[[@b28-medscimonit-22-3915]\]. The results of the present study showed that the staining intensity of βIII-tubulin was associated with the lymphatic metastasis in the non-invasive front group, suggesting the potential role of βIII-tubulin in tumor invasion or metastasis. However, our study showed no significant association of βIII-tubulin with tumor recurrence, metastasis, or survival. Further research is needed to clarify the potential role of βIII-tubulin in colorectal cancer and patient prognosis.

This study has some limitations. The number of patients recruited in was comparatively small. Therefore, only the patients with βIII-tubulin expressed in the invasive front of tumor tissue were included in the invasive front group, and all remaining patients were included in the non-invasive front group. However, despite these limitations, our study did show the association of βIII-tubulin expression with tumor differentiation and lymphatic metastasis in colorectal cancer. Studies with larger samples are needed to further clarify the clinical implications of βIII-tubulin expression at the invasive margin in colorectal cancer.

Conclusions
===========

Our data showed the tissue distribution of class III β-tubulin expression at the invasive margin or diffuse distribution, and that βIII-tubulin expression may be involved in tumor differentiation and metastasis. This study may shed light on βIII-tubulin as a novel potential molecular target for new anti-cancer drugs.
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![Histological and immunohistochemical analysis of colorectal cancer. HE staining of tumor tissue in the non-invasive front group (**A**, ×50) and invasive front group (**B**, ×50). Immunohistochemical staining of cytokeratin AE1/AE3 in the non-invasive front group (**C**, ×50) and invasive front group (**D**, ×50). Immunohistochemical analysis of βIII-tubulin with different positive intensities in the non-invasive front group (**E**: +; **G**: ++; **I**: +++; **E**, ×100, **G** and **I**, ×50) and invasive front group (**F**: +; **H**: ++; **J**: +++) (**E, F**, ×100, strong positivity of βIII-tubulin in nervous tissue as internal control; **G--J**, ×50).](medscimonit-22-3915-g001){#f1-medscimonit-22-3915}

![Positive staining (**A**) and staining intensity of βIII-tubulin (**B**) and tumor differentiation (**C**) were significantly different in patients in the invasive and non-invasive front groups. Staining intensity of βIII-tubulin was significantly associated with lymphatic metastasis in the non-invasive front group (**D**). \*\* p\<0.01 *vs.* the non-invasive front group.](medscimonit-22-3915-g002){#f2-medscimonit-22-3915}

###### 

Clinical data of patients with colorectal carcinoma.

                                                      Colorectal carcinoma patients (n=111)
  --------------------------------------------------- ---------------------------------------
  **Age (years)**                                     66.41±12.64
  **Gender n (%)**                                    
   Male                                               55
   Female                                             56
  **Lymphatic metastasis n (%)**                      
   No                                                 54 (48.65)
   Yes                                                57 (51.35)
  **Tumor differentiation n (%)**                     
   Well                                               18 (16.22)
   Moderate                                           68 (61.26)
   Poor                                               25 (22.52)
  **TNM stage n (%)**                                 
   I                                                  18 (16.22)
   II                                                 35 (31.53)
   III                                                46 (41.44)
   IV                                                 12 (10.81)
  **Local recurrence n (%)**                          
   No                                                 109 (98.20%)
   Yes                                                2 (1.80)
  **Distant metastasis n (%)**                        
   No                                                 97 (87.39%)
   Yes                                                14 (12.61)
  **Mortality n (%)**                                 
   No                                                 102 (91.89)
   Yes                                                9 (8.11)
  **Positive staining of** β**III-tubulin (%)**       0.31±0.27
  **Staining intensity of** β**III-tubulin n (%)**    
   −                                                  6 (5.41)
   +                                                  10 (9.01)
   ++                                                 65 (58.56)
   +++                                                30 (27.03)
  **Tissue distribution of** β**III-tubulin n (%)**   
   Invasive front group                               72 (64.87)
   Non-invasive front group                           39 (35.13)

###### 

Clinical analysis of positive staining of βIII-tubulin in colorectal carcinoma patients.

                                                Case (n)   Positive staining of bIII-tubulin (%)   *t*     *P*
  --------------------------------------------- ---------- --------------------------------------- ------- -------
  **Age**                                       111        --                                      −0.02   0.836
  **Gender**                                                                                               
   Male                                         55         0.32±0.27                               0.17    0.869
   Female                                       56         0.31±0.27                                       
  **Lymphatic metastasis**                                                                                 
   No                                           54         0.32±0.25                               0.15    0.878
   Yes                                          57         0.31±0.29                                       
  **Tumor differentiation**                                                                                
   Well                                         18         0.40±0.30                               1.76    0.177
   Moderate                                     68         0.28±0.25                                       
   Poor                                         25         0.34±0.29                                       
  **TNM stage**                                                                                            
   I                                            18         0.44±0.31a                              1.62    0.189
   II                                           35         0.28±0.21a                                      
   III                                          46         0.30±0.29a                                      
   IV                                           12         0.28±0.26a                                      
  **Local recurrence**                                                                                     
   No                                           109        0.31±0.27                               −0.35   0.783
   Yes                                          2          0.47±0.62                                       
  **Distant metastasis**                                                                                   
   No                                           97         0.32±0.27                               0.16    0.875
   Yes                                          14         0.30±0.30                                       
  **Mortality**                                                                                            
   No                                           102        0.31±0.27                               −0.58   0.566
   Yes                                          9          0.36±0.33                                       
  **Staining intensity of** β**III-tubulin**                                                               
   −                                            6          0.00±0.00b                              3.49    0.018
   +                                            10         0.24±0.31a                                      
   ++                                           65         0.34±0.26a                                      
   +++                                          30         0.34±0.28a                                      
  **Tissue distribution of** β**III-tubulin**                                                              
  Non-invasive front group                      39         0.44±0.33                               3.52    0.001
  Invasive front group                          72         0.24±0.20                                       

###### 

Clinical analysis of staining intensity of βIII-tubulin in colorectal carcinoma patients.

                                                  Staining intensity of βIII-tubulin   χ^2^                                                            *P*                                                                                                                                                                                        
  ----------------------------------------------- ------------------------------------ --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------- -------
  **Age (years)**                                 59.83±21.64                          66.90±12.01                                                     66.65±11.37                                                     67.03±13.62                                                     0.57[\*](#tfn1-medscimonit-22-3915){ref-type="table-fn"}   0.635
  **Gender n (%)**                                                                                                                                                                                                                                                                                                                                
   Male                                           3 (50.00)                            6 (60.00)                                                       33 (50.77)                                                      13 (43.33)                                                      0.01                                                       0.829
   Female                                         3 (50.00)                            4 (40.00)                                                       32 (49.23)                                                      17 (56.67)                                                                                                                 
  **Lymphatic metastasis**                                                                                                                                                                                                                                                                                                                        
   No                                             5 (83.33)                            4 (40.00)                                                       31 (47.69)                                                      14 (46.67)                                                      0.00                                                       0.383
   Yes                                            1 (16.67)                            6 (60.00)                                                       34 (52.31)                                                      16 (53.33)                                                                                                                 
  **Tumor differentiation n (%)**                                                                                                                                                                                                                                                                                                                 
   Well                                           3 (50.00)                            1 (10.00)                                                       12 (18.46)                                                      2 (6.67)                                                        0.00                                                       0.078
   Moderate                                       1 (16.67)                            6 (60.00)                                                       42 (64.62)                                                      19 (63.33)                                                                                                                 
   Poor                                           2 (33.33)                            3 (30.00)                                                       11 (16.92)                                                      9 (30.00)                                                                                                                  
  **TNM stage**                                                                                                                                                                                                                                                                                                                                   
   I                                              1 (16.67)                            3 (30.00)                                                       10 (15.38)                                                      4 (13.33)                                                       0.00                                                       0.597
   II                                             4 (66.67)                            1 (10.00)                                                       22 (33.85)                                                      8 (26.67)                                                                                                                  
   III                                            1 (16.67)                            5 (50.00)                                                       26 (40.00)                                                      14 (46.67)                                                                                                                 
   IV                                             0 (0.00)                             1 (10.00)                                                       7 (10.77)                                                       4 (13.33)                                                                                                                  
  **Local recurrence**                                                                                                                                                                                                                                                                                                                            
   No                                             6 (100.0)                            9 (90.00)                                                       65 (100.0)                                                      29 (96.67)                                                      0.05                                                       0.100
   Yes                                            0 (0.00)                             1 (10.00)                                                       0 (0.00)                                                        1 (3.33)                                                                                                                   
  **Distant metastasis**                                                                                                                                                                                                                                                                                                                          
   No                                             5 (83.33)                            9 (90.00)                                                       58 (89.23)                                                      25 (83.33)                                                      0.03                                                       0.785
   Yes                                            1 (16.67)                            1 (10.00)                                                       7 (10.77)                                                       5 (16.67)                                                                                                                  
  **Mortality**                                                                                                                                                                                                                                                                                                                                   
   No                                             6 (100.0)                            9 (90.00)                                                       60 (92.31)                                                      27 (90.00)                                                      0.07                                                       0.932
   Yes                                            0 (0.00)                             1 (10.00)                                                       5 (7.69)                                                        3 (10.00)                                                                                                                  
  **Positive staining of** β**III-tubulin (%)**   0.00±0.00                            0.24±0.31[\*](#tfn1-medscimonit-22-3915){ref-type="table-fn"}   0.34±0.26[\*](#tfn1-medscimonit-22-3915){ref-type="table-fn"}   0.34±0.28[\*](#tfn1-medscimonit-22-3915){ref-type="table-fn"}   3.49                                                       0.018

p\<0.05 *vs.* the βIII-tubulin negative (−) group.

###### 

Clinical analysis of patients with βIII-tubulin distributed in invasive front and non-invasive front area.

                                                  Colorectal carcinoma patients   χ^2^          *P*     
  ----------------------------------------------- ------------------------------- ------------- ------- -------
  **Age (years)**                                 64.79±14.40                     67.28±11.59   −0.99   0.325
  **Gender n (%)**                                                                                      
   Male                                           22 (56.41)                      33 (45.83)    1.13    0.287
   Female                                         17 (43.59)                      39 (54.17)            
  **Lymphatic metastasis**                                                                              
   No                                             19 (48.72)                      35 (48.61)    0.00    0.991
   Yes                                            20 (51.28)                      37 (51.39)            
  **Tumor differentiation n (%)**                                                                       
   Well                                           11 (28.21)                      7 (9.72)      6.88    0.032
   Moderate                                       19 (48.72)                      49 (68.06)            
   Poor                                           9 (23.08)                       16 (22.22)            
  **TNM stage**                                                                                         
   I                                              8 (20.51)                       10 (13.89)    3.01    0.390
   II                                             11 (28.21)                      24 (33.33)            
   III                                            18 (46.15)                      28 (38.89)            
   IV                                             2 (5.13)                        10 (13.89)            
  **Local recurrence**                                                                                  
   No                                             38 (97.44)                      71 (98.61)    0.46    1.000
   Yes                                            1 (2.56)                        1 (1.39)              
  **Distant metastasis**                                                                                
   No                                             35 (89.74)                      62 (86.11)    0.21    0.767
   Yes                                            4 (10.26)                       10 (13.89)            
  **Mortality**                                                                                         
   No                                             35 (89.74)                      67 (93.06)    0.23    0.717
   Yes                                            4 (10.26)                       5 (6.94)              
  **Staining intensity of** β**III-tubulin**                                                            
   −                                              6 (15.38)                       0 (0.00)      0.00    0.006
   +                                              2 (5.13)                        8 (11.11)             
   ++                                             23 (58.97)                      42 (58.33)            
   +++                                            8 (20.51)                       22 (30.56)            
  **Positive staining of** β**III-tubulin (%)**   0.44±0.33                       0.24±0.20     3.52    0.001

###### 

clinical analysis of βIII-tubulin staining intensity in patients of invasive and non-invasive front groups.

                                                  Colorectal carcinoma patients                                                                                                                                                                                                                                                                             
  ----------------------------------------------- ------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- ----------- ------------ ------------- ------------- ------------- ------ -------
  **Age (years)**                                 59.83±21.64                     63.50±7.78                                                      64.74±11.63                                                     69.00±17.78                                                     0.45        0.719        67.75±13.14   67.69±11.23   66.32±12.19   0.11   0.9
  **Gender n (%)**                                                                                                                                                                                                                                                                                                                                          
   Male                                           3 (50.00)                       1 (50.00)                                                       13 (56.52)                                                      5 (62.50)                                                       0.05        1            5 (62.50)     20 (47.62)    8 (36.36)     0.03   0.422
   Female                                         3 (50.00)                       1 (50.00)                                                       10 (43.48)                                                      3 (37.50)                                                       3 (37.50)   22 (52.38)   14 (63.64)                                       
  **Lymphatic metastasis**                                                                                                                                                                                                                                                                                                                                  
   No                                             5 (83.33)                       1 (50.00)                                                       12 (52.17)                                                      1 (12.50)                                                       0           0.048        3 (37.50)     19 (45.24)    13 (59.09)    0.03   0.515
   Yes                                            1 (16.67)                       1 (50.00)                                                       11 (47.83)                                                      7 (87.50)                                                       5 (62.50)   23 (54.76)   9 (40.91)                                        
  **Tumor differentiation n (%)**                                                                                                                                                                                                                                                                                                                           
   Well                                           3 (50.00)                       1 (50.00)                                                       7 (30.43)                                                       0 (0.00)                                                        0           0.185        0 (0.00)      5 (11.90)     2 (9.09)      0      0.633
   Moderate                                       1 (16.67)                       1 (50.00)                                                       12 (52.17)                                                      5 (62.50)                                                       5 (62.50)   30 (71.43)   14 (63.64)                                       
   Poor                                           2 (33.33)                       0 (0.00)                                                        4 (17.39)                                                       3 (37.50)                                                       3 (37.50)   7 (16.67)    6 (27.27)                                        
  **TNM stage**                                                                                                                                                                                                                                                                                                                                             
   I                                              1 (16.67)                       1 (50.00)                                                       5 (21.74)                                                       1 (12.50)                                                       0           0.169        2 (25.00)     5 (11.90)     3 (13.64)     0      0.876
   II                                             4 (66.67)                       0 (0.00)                                                        7 (30.43)                                                       0 (0.00)                                                        1 (12.50)   15 (35.71)   8 (36.36)                                        
   III                                            1 (16.67)                       1 (50.00)                                                       10 (43.48)                                                      6 (75.00)                                                       4 (50.00)   16 (38.10)   8 (36.36)                                        
   IV                                             0 (0.00)                        0 (0.00)                                                        1 (4.35)                                                        1 (12.50)                                                       1 (12.50)   6 (14.29)    3 (13.64)                                        
  **Local recurrence**                                                                                                                                                                                                                                                                                                                                      
   No                                             6 (100.0)                       2 (100.0)                                                       23 (100.0)                                                      7 (87.50)                                                       0.21        0.414        7 (87.50)     42 (100.0)    22 (100.0)    0.11   0.110
   Yes                                            0 (0.00)                        0 (0.00)                                                        0 (0.00)                                                        1 (12.50)                                                       1 (12.50)   0 (0.00)     0 (0.00)                                         
  **Distant metastasis**                                                                                                                                                                                                                                                                                                                                    
   No                                             5 (83.33)                       2 (100.0)                                                       22 (95.65)                                                      6 (75.00)                                                       0.05        0.302        7 (87.50)     36 (85.71)    19 (86.36)    0.12   1.000
   Yes                                            1 (16.67)                       0 (0.00)                                                        1 (4.35)                                                        2 (25.00)                                                       1 (12.50)   6 (14.29)    3 (13.64)                                        
  **Mortality**                                                                                                                                                                                                                                                                                                                                             
   No                                             6 (100.0)                       2 (100.0)                                                       21 (91.30)                                                      6 (75.00)                                                       0.09        0.449        7 (87.50)     39 (92.86)    21 (95.45)    0.14   0.640
   Yes                                            0 (0.00)                        0 (0.00)                                                        2 (8.70)                                                        2 (25.00)                                                       1 (12.50)   3 (7.14)     1 (4.55)                                         
  **Positive staining of** β**III-tubulin (%)**   0.00±0.00                       0.80±0.00[\*](#tfn2-medscimonit-22-3915){ref-type="table-fn"}   0.46±0.28[\*](#tfn2-medscimonit-22-3915){ref-type="table-fn"}   0.64±0.27[\*](#tfn2-medscimonit-22-3915){ref-type="table-fn"}   8.91        \<0.001      0.10±0.10     0.27±0.21     0.24±0.20     2.47   0.092

p\<0.05 *vs.* the βIII-tubulin negative (−) group.
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